
Supplementary Online Content

Kusamura S, Barretta F, Yonemura Y, et al; Peritoneal Surface Oncology Group International (PSOGI) and the French National Registry of Rare Peritoneal Surface Malignancies (RENAPE). The role of hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei after cytoreductive surgery. *JAMA Surg.* Published online January 27, 2021. doi:10.1001/jamasurg.2020.6363


- **eFigure 1.** Flowchart of Patients Selected for the Analysis (Unweighted Numbers)
- eFigure 2. Kaplan-Meier Overall Survival Curves According to Treatment
- eTable 1. HIPEC Schedules
- **eTable 2.** Distribution of Prognostic Factors Between the Study Groups Before and After IPTW Weighting Adjustment in CC-0/1 Cases
- **eTable 3.** Distribution of Prognostic Factors Between the Study Groups Before and After IPTW Weighting Adjustment in CC-2/3 Cases
- **eTable 4.** Distribution of Prognostic Factors Between the Study Groups Before and After IPTW Weighting Adjustment in Low-Grade Disease
- **eTable 5.** Distribution of Prognostic Factors Between the Study Groups Before and After IPTW Weighting Adjustment in High-Grade Disease
- **eTable 6.** Distribution of Prognostic Factors Between the Study Groups Before and After IPTW Weighting Adjustment for HIPEC With Cisplatin Plus Mitomycin
- **eTable 7.** Distribution of Prognostic Factors Between the Study Groups Before and After IPTW Weighting Adjustment for HIPEC With Mitomycin
- **eTable 8.** Distribution of Prognostic Factors Between the Study Groups Before and After IPTW Weighting Adjustment for HIPEC With Oxaliplatin Plus Fluorouracil/Leucovorin
- **eTable 9.** Distribution of Prognostic Factors Between the Study Groups Before and After IPTW Weighting Adjustment for HIPEC With Other Oxaliplatin-Based Combinations
- **eTable 10.** Surgical Outcomes of Patients With PMP Undergoing CRS-HIPEC (n = 1548) and CRS Alone (n = 376)
- **eTable 11.** Unweighted Comparison of the Distribution of the Prognostic Factors and Outcomes Between Included and Excluded Cases
- **eTable 12.** Unweighted Distribution of Prognostic Factors Between the Study Groups in the Cases That Were Excluded Due to Incomplete Data

This supplementary material has been provided by the authors to give readers additional information about their work.

eFigure 1. Flowchart of Patients Selected for the Analysis (Unweighted Numbers)



eFigure 2. Kaplan-Meier Overall Survival Curves According to Treatment



Includes CRS+HIPEC vs CRS alone in CC-0/1 patients (A), CC-2/3 patients (B), low-grade patients (C), and high-grade patients (D).

eTable 1. HIPEC Schedules

Intraperitoneal drug schedules	Drug 1	Drug 2	Drug 3	Perfusate	Duration	Temperature (°C)	Modality of perfusion
MMC 1	35 mg/M ²	-	-	PDS	90 min	42.0-43.0	open
MMC 2	40 mg fixed-dose	-	-	NS 3 L fixed volume	120 min	42.0	closed
CDDP MMC	Cisplatin 25 mg/M ² /L of perfusate	MMC 3.3 mg/L/M ²	-	NS+ colloid 2.5 L /m2	60 min	42.5	closed
Oxaliplatin + 5- FU/LV	Oxaliplatin 460 mg/M2	5-FU	LV	D5W 2.0 L/m2	30 min	43.0	open
Oxaliplatin + 5- FU/LV	Oxaliplatin 360 mg/M2	5-FU	LV	D5W 4-6L	30 min	42.0	closed
Other oxaliplatin	200 mg/M2	-	-	NS 3 L fixed volume	120 min	40.0	closed

MMC: mitomycin-C; CDDP: cisplatin; LV: leucovorin; POD:postoperative day; PDS: peritoneal dialysis solution; NS: normal saline; D5W, dextrose 5%

eTable 2. Distribution of Prognostic Factors Between the Study Groups Before and After IPTW Weighting Adjustment in CC-0/1 Cases

Unweighted comparison

	_	. 5		
_		CRS alone	CRS/HIPEC	SMD
n (GE)		164	1352	0 1 4 4
Age (mean (SD))		55.36 (14.43)		
Priorche = 1 (%)		69 (42.1)	423 (31.3)	0.225
LN = 1 (%)			94 (7.0)	0.117
PCI (mean (SD))		14.45 (11.48)	17.94 (10.67)	0.315
PSS (%)				0.346
0		52 (31.7)	287 (21.2)	
1		48 (29.3)	413 (30.5)	
2		51 (31.1)	413 (30.5)	
3		13 (7.9)	239 (17.7)	
CC (%)	1	57 (34.8)	473 (35.0)	0.005
Epic (%)	1	37 (22.6)	225 (16.6)	0.150
Histol (%)	1	59 (36.0)	388 (28.7)	0.156
1113001 (8)	_	33 (30:0)	300 (20:7)	0.130
	Wei	ghted comparison		
		CRS alone	CRS/HIPEC	SMD
n		163.61	163.71	
Age (mean (SD))		55.31 (14.41)	55.38 (13.99)	0.005
Priorche (%)	1	68.7 (42.0)	70.9 (43.3)	0.027
LN (%)	1		6.7 (4.1)	0.011
PCI (mean (SD))		14.47 (11.48)	14.59 (11.45)	0.011
PSS (%)		14.47 (11.40)	14.35 (11.43)	0.010
0		51.7 (31.6)	50.5 (30.9)	0.022
1		48.0 (29.3)	48.5 (29.6)	
2 3		50.9 (31.1)	52.1 (31.8)	
		13.0 (7.9)	12.6 (7.7)	
CC (%)	1	163.6 (100.0)	163.7 (100.0)	<0.001
Epic (%)	1	37.0 (22.6)	38.6 (23.6)	0.023
Histol (%)	1	58.7 (35.9)	58.7 (35.9)	<0.001

eTable 3. Distribution of Prognostic Factors Between the Study Groups Before and After IPTW Weighting Adjustment in CC-2/3 Cases

Unweighted	comparison

	onweighted co	mparison			
n	CRS al 212	one	CRS/HI 196	IPEC	SMD
Age (mean (SD))	61.66	(13.95)	56.12	(13.81)	0.399
Priorche = 1 (%)		(60.8)		(54.1)	0.137
LN = 1 (%)		(3.3)		(12.8)	0.353
PCI (mean (SD))		(8.91)		(7.80)	0.028
PSS (%)	33.33	(3,31)	00.02	(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	0.373
0	66	(31.1)	68	(34.7)	0.070
1		(24.1)		(27.6)	
2		(36.8)		(21.9)	
3		(8.0)		(15.8)	
CC = 3 (%)		(82.5)		(59.7)	0.521
3 (0)	175	(02.0)	±± /	(33.7)	0.321
Epic = 1 (%)	16	(7.5)	25	(12.8)	0.173
Histol = 2 (%)		(56.6)		(53.1)	0.071
	Weighted comp	parison			
	CRS al	one	CRS/HI	IPEC	SMD
n	146.57	1	144.60)	
Age (mean (SD))	58.48	(13.62)	58.72	(13.39)	0.018
Priorche = $1 (%)$	84.9	(57.9)	84.9	(58.7)	0.017
LN = 1 (%)	6.8	3 (4.6)	6.3	(4.4)	0.012
PCI (mean (SD))	30.72	(7.95)	30.75	(7.89)	0.004
PSS (%)					0.036
0	48.3	(33.0)	48.8	(33.7)	
1	40.9	(27.9)	41.7	(28.8)	
2	41.7	(28.5)	39.0	(27.0)	
3	15.6	(10.6)	15.2	(10.5)	
CC = 3 (%)		(83.3)	94.9	(65.6)	0.416
Epic = $1 (%)$	13.8	3 (9.4)		(9.9)	0.017
Histol = 2 (%)	79.1	(54.0)	79.3	(54.9)	0.018

eTable 4. Distribution of Prognostic Factors Between the Study Groups Before and After IPTW Weighting Adjustment in Low-Grade Disease

Unweighted	comparison
------------	------------

	omparious comparion		
n	CRS alone 197	CRS/HIPEC 1056	SMD
Age (mean (SD))	59.42 (14.87)	54.35 (12.40)	0.371
Priorche = 1 (%)	78 (39.6)	279 (26.4)	0.283
LN = 1 (%)	2 (1.0)	25 (2.4)	0.105
PCI (mean (SD))		18.39 (10.74)	0.255
CC (%)	21.40 (13.30)	10.33 (10.74)	0.964
1	105 (53.3)	964 (91.3)	
2	16 (8.1)	41 (3.9)	
3	76 (38.6)	51 (4.8)	
PSS (%)			0.282
0	56 (28.4)	225 (21.3)	
1	53 (26.9)		
2	66 (33.5)		
3	22 (11.2)		
Epic = 1 (%)	24 (12.2)		0.035
1 - (- ,	,	,	
	Weighted comparison		
	CRS alone	CRS/HIPEC	SMD
n	167.63	164.68	SMD
Age (mean (SD))	57.55 (14.65)		0 011
Priorche = 1 (%)			0.023
	1.7 (1.0)		
LN = 1 (%)	19.54 (12.87)		0.005 0.002
PCI (mean (SD))	19.54 (12.67)	19.52 (12.59)	
CC (%)	105 0 (60 6)	105 0 (62 0)	0.051
1	105.0 (62.6)		
2	-	13.3 (8.1)	
3	46.7 (27.9)	46.1 (28.0)	
PSS (%)			0.049
0	43.2 (25.8)		
1	48.3 (28.8)		
2	56.2 (33.6)		
3	19.8 (11.8)		
Epic = 1 (%)	01 1 (10 6)	00 4 (40 6)	0 001
EPIC - I (%)	21.1 (12.6)	22.4 (13.6)	0.031

eTable 5. Distribution of Prognostic Factors Between the Study Groups Before and After IPTW Weighting Adjustment in High-Grade Disease

IIntroight	-od com	narican
Unweight	tea com	nparison

	omparison comparison		
n	CRS alone 179	CRS/HIPEC 492	SMD
	58.35 (14.07)	_	0.438
Age (mean (SD))	120 (67 0)	250 (50.0)	
Priorche = 1 (%)	120 (67.0) 12 (6.7) 25.23 (11.81)	250 (50.8)	0.334
LN = 1 (%)	12 (6.7)	94 (19.1)	0.376
PCI (mean (SD))	25.23 (11.81)	21.89 (11.61)	0.285
CC (%)			1.081
1	59 (33.0)	388 (78.9)	
2	21 (11.7)	38 (7.7)	
3	99 (55.3)	66 (13.4)	
PSS (%)	33 (33.3)	(10.1)	0.412
0	62 (34.6)	130 (26.4)	0.112
		114 (22.2)	
1	46 (25.7)	114 (23.2)	
2	63 (35.2)	167 (33.9)	
3	8 (4.5)	81 (16.5)	
Epic = 1 (%)	29 (16.2)	109 (22.2)	0.152
	Weighted comparison		
	Weighted comparison		
		CRS/HIPEC	SMD
n		CRS/HIPEC 135.71	SMD
	CRS alone 137.09	135.71	
Age (mean (SD))	CRS alone 137.09 55.93 (13.46)	135.71 55.87 (13.32)	0.004
Age (mean (SD)) Priorche = 1 (%)	CRS alone 137.09 55.93 (13.46) 87.6 (63.9)	135.71 55.87 (13.32) 85.9 (63.3)	0.004 0.013
Age (mean (SD)) Priorche = 1 (%) LN = 1 (%)	CRS alone 137.09 55.93 (13.46) 87.6 (63.9) 10.6 (7.7)	135.71 55.87 (13.32) 85.9 (63.3) 10.8 (8.0)	0.004 0.013 0.008
Age (mean (SD)) Priorche = 1 (%) LN = 1 (%) PCI (mean (SD))	CRS alone 137.09 55.93 (13.46) 87.6 (63.9)	135.71 55.87 (13.32) 85.9 (63.3) 10.8 (8.0)	0.004 0.013 0.008 0.004
Age (mean (SD)) Priorche = 1 (%) LN = 1 (%) PCI (mean (SD)) CC (%)	CRS alone 137.09 55.93 (13.46) 87.6 (63.9) 10.6 (7.7) 24.69(12.42)	135.71 55.87 (13.32) 85.9 (63.3) 10.8 (8.0) 24.63 (12.11)	0.004 0.013 0.008
Age (mean (SD)) Priorche = 1 (%) LN = 1 (%) PCI (mean (SD)) CC (%) 1	CRS alone 137.09 55.93 (13.46) 87.6 (63.9) 10.6 (7.7) 24.69(12.42) 58.9 (43.0)	135.71 55.87 (13.32) 85.9 (63.3) 10.8 (8.0) 24.63 (12.11)	0.004 0.013 0.008 0.004
Age (mean (SD)) Priorche = 1 (%) LN = 1 (%) PCI (mean (SD)) CC (%) 1 2	CRS alone 137.09 55.93 (13.46) 87.6 (63.9) 10.6 (7.7) 24.69(12.42) 58.9 (43.0) 20.2 (14.7)	135.71 55.87 (13.32) 85.9 (63.3) 10.8 (8.0) 24.63 (12.11) 60.8 (44.8) 14.4 (10.6)	0.004 0.013 0.008 0.004
Age (mean (SD)) Priorche = 1 (%) LN = 1 (%) PCI (mean (SD)) CC (%) 1 2 3	CRS alone 137.09 55.93 (13.46) 87.6 (63.9) 10.6 (7.7) 24.69(12.42) 58.9 (43.0)	135.71 55.87 (13.32) 85.9 (63.3) 10.8 (8.0) 24.63 (12.11) 60.8 (44.8) 14.4 (10.6)	0.004 0.013 0.008 0.004
Age (mean (SD)) Priorche = 1 (%) LN = 1 (%) PCI (mean (SD)) CC (%) 1 2	CRS alone 137.09 55.93 (13.46) 87.6 (63.9) 10.6 (7.7) 24.69(12.42) 58.9 (43.0) 20.2 (14.7)	135.71 55.87 (13.32) 85.9 (63.3) 10.8 (8.0) 24.63 (12.11) 60.8 (44.8) 14.4 (10.6)	0.004 0.013 0.008 0.004
Age (mean (SD)) Priorche = 1 (%) LN = 1 (%) PCI (mean (SD)) CC (%) 1 2 3	CRS alone 137.09 55.93 (13.46) 87.6 (63.9) 10.6 (7.7) 24.69(12.42) 58.9 (43.0) 20.2 (14.7) 58.0 (42.3)	135.71 55.87 (13.32) 85.9 (63.3) 10.8 (8.0) 24.63 (12.11) 60.8 (44.8) 14.4 (10.6) 60.5 (44.6)	0.004 0.013 0.008 0.004 0.124
Age (mean (SD)) Priorche = 1 (%) LN = 1 (%) PCI (mean (SD)) CC (%) 1 2 3 PSS (%) 0	CRS alone 137.09 55.93 (13.46) 87.6 (63.9) 10.6 (7.7) 24.69(12.42) 58.9 (43.0) 20.2 (14.7) 58.0 (42.3) 42.0 (30.6)	135.71 55.87 (13.32) 85.9 (63.3) 10.8 (8.0) 24.63 (12.11) 60.8 (44.8) 14.4 (10.6) 60.5 (44.6) 45.2 (33.3)	0.004 0.013 0.008 0.004 0.124
Age (mean (SD)) Priorche = 1 (%) LN = 1 (%) PCI (mean (SD)) CC (%) 1 2 3 PSS (%) 0 1	CRS alone 137.09 55.93 (13.46) 87.6 (63.9) 10.6 (7.7) 24.69(12.42) 58.9 (43.0) 20.2 (14.7) 58.0 (42.3) 42.0 (30.6) 35.7 (26.0)	135.71 55.87 (13.32) 85.9 (63.3) 10.8 (8.0) 24.63 (12.11) 60.8 (44.8) 14.4 (10.6) 60.5 (44.6) 45.2 (33.3) 39.8 (29.3)	0.004 0.013 0.008 0.004 0.124
Age (mean (SD)) Priorche = 1 (%) LN = 1 (%) PCI (mean (SD)) CC (%) 1 2 3 PSS (%) 0 1 2	CRS alone 137.09 55.93 (13.46) 87.6 (63.9) 10.6 (7.7) 24.69(12.42) 58.9 (43.0) 20.2 (14.7) 58.0 (42.3) 42.0 (30.6) 35.7 (26.0) 52.4 (38.3)	135.71 55.87 (13.32) 85.9 (63.3) 10.8 (8.0) 24.63 (12.11) 60.8 (44.8) 14.4 (10.6) 60.5 (44.6) 45.2 (33.3) 39.8 (29.3) 38.5 (28.4)	0.004 0.013 0.008 0.004 0.124
Age (mean (SD)) Priorche = 1 (%) LN = 1 (%) PCI (mean (SD)) CC (%) 1 2 3 PSS (%) 0 1	CRS alone 137.09 55.93 (13.46) 87.6 (63.9) 10.6 (7.7) 24.69(12.42) 58.9 (43.0) 20.2 (14.7) 58.0 (42.3) 42.0 (30.6) 35.7 (26.0)	135.71 55.87 (13.32) 85.9 (63.3) 10.8 (8.0) 24.63 (12.11) 60.8 (44.8) 14.4 (10.6) 60.5 (44.6) 45.2 (33.3) 39.8 (29.3)	0.004 0.013 0.008 0.004 0.124

eTable 6. Distribution of Prognostic Factors Between the Study Groups Before and After IPTW Weighting Adjustment for HIPEC With Cisplatin Plus Mitomycin

Unweig	hted	comparison

	Unweighted Comparison		
	CRS	CRS/HIPEC	SMD
n	376	709	
Age (mean (SD))	58.91 (14.48)	53.96 (12.74)	0.363
Priorche = 1 (%)	198 (52.7)	272 (38.4)	0.290
LN = 1 (%)	14 (3.7)	29 (4.1)	0.019
PCI (mean (SD))	23.26 (12.74)		0.397
CC (%)			1.032
1	164 (43.6)	616 (86.9)	1.002
2	37 (9.8)	29 (4.1)	
3	175 (46.5)	64 (9.0)	
PSS (%)	173 (40.3)	04 (3.0)	0.155
0	118 (31.4)	182 (25.7)	0.133
1	99 (26.3)	227 (32.0)	
2		257 (32.0)	
3	129 (34.3)		
	30 (8.0)	50 (7.1)	0 005
Epic = 1 (%)	53 (14.1)	80 (11.3)	0.085
Histol = 2 (%)	179 (47.6)	223 (31.5)	0.335
	Weighted comparison		
	CRS	CRS/HIPEC	SMD
n	256.57	252.04	0112
Age (mean (SD))	56.31 (13.92)	56.28 (13.67)	0.001
Priorche = 1 (%)		124.0 (49.2)	0.017
LN = 1 (%)	10.8 (4.2)	11.8 (4.7)	0.025
PCI (mean (SD))	20.07 (12.76)	19.91 (12.77)	0.012
CC (%)	20.07 (12.70)	19.91 (12.77)	0.012
1	163.4 (63.7)	166.4 (66.0)	0.115
2	31.1 (12.1)	21.8 (8.6)	0.113
3	62.0 (24.2)	63.9 (25.3)	
PSS (%)	02.0 (24.2)	03.9 (23.3)	
0	74.1 (28.9)	73.9 (29.3)	0.018
1		73.9 (29.3)	0.010
	73.9 (28.8)		
2	88.0 (34.3)	84.7 (33.6)	
2 3	88.0 (34.3) 20.5 (8.0)	84.7 (33.6) 19.7 (7.8)	0 022
2	88.0 (34.3)	84.7 (33.6)	0.022 0.010

eTable 7. Distribution of Prognostic Factors Between the Study Groups Before and After IPTW Weighting Adjustment for HIPEC With Mitomycin

Unweighted comparison

	omparison comparison	•	
n		CRS/HIPEC 547	SMD
	58 95 (14 49)	52.82 (12.06)	0 460
Priorche = 1 (2)	198 (52 5)	1/7 (26 9)	0.400
IIIOICHE — I (8)	14 (37)	147 (26.9) 71 (13.0) 21.48 (11.22)	0.340
DCT (moon (SD))	22 20 (12 72)	71 (13.0)	0.340
	23.20 (12.72)	21.40 (11.22)	
CC (%)	1.65 (40.0)	456 (05 0)	1.124
1		476 (87.0)	
2	37 (9.8)	44 (8.0)	
3	175 (46.4)	27 (4.9)	
PSS (%)			0.545
0	118 (31.3)	113 (20.7)	
1	99 (26.3)	115 (20.7) 151 (27.6) 137 (25.0)	
2	130 (34.5)	137 (25.0)	
3	30 (8.0)	146 (26.7)	
Epic = 1 (%)	53 (14.1)	162 (29.6)	0.383
Histol = 2 (%)	179 (47.5)	187 (34.2)	0.273
	Weighted compariso	on	
	CRS alone	CRS/HIPEC	SMD
n	193.55	196.03	
Age (mean (SD))		55.47(13.45)	0.019
		78.7 (40.1)	
LN = 1 (%)		10.4 (5.3)	
		19.22 (11.93)	
	10.20 (12.71)		
CC (%)			
CC (%)		0.098	
1	148.0 (76.5)	0.098 145.8 (74.4)	
1 2	148.0 (76.5) 19.0 (9.8)	0.098 145.8 (74.4) 25.2 (12.9)	
1 2 3	148.0 (76.5)	0.098 145.8 (74.4)	
1 2 3 PSS (%)	148.0 (76.5) 19.0 (9.8) 26.6 (13.7)	0.098 145.8 (74.4) 25.2 (12.9) 25.0 (12.8)	0.044
1 2 3 PSS (%)	148.0 (76.5) 19.0 (9.8) 26.6 (13.7) 52.1 26.9)	0.098 145.8 (74.4) 25.2 (12.9) 25.0 (12.8) 50.3 (25.7)	
1 2 3 PSS (%) 0 1	148.0 (76.5) 19.0 (9.8) 26.6 (13.7) 52.1 26.9) 54.5 (28.1)	0.098 145.8 (74.4) 25.2 (12.9) 25.0 (12.8) 50.3 (25.7) 53.7 (27.4)	
1 2 3 PSS (%) 0 1 2	148.0 (76.5) 19.0 (9.8) 26.6 (13.7) 52.1 26.9) 54.5 (28.1) 62.4 (32.2)	0.098 145.8 (74.4) 25.2 (12.9) 25.0 (12.8) 50.3 (25.7) 53.7 (27.4) 67.0 (34.2)	
1 2 3 PSS (%) 0 1 2	148.0 (76.5) 19.0 (9.8) 26.6 (13.7) 52.1 26.9) 54.5 (28.1) 62.4 (32.2) 24.7 (12.7)	0.098 145.8 (74.4) 25.2 (12.9) 25.0 (12.8) 50.3 (25.7) 53.7 (27.4) 67.0 (34.2) 25.1 (12.8)	0.044
1 2 3 PSS (%) 0 1 2	148.0 (76.5) 19.0 (9.8) 26.6 (13.7) 52.1 26.9) 54.5 (28.1) 62.4 (32.2) 24.7 (12.7)	0.098 145.8 (74.4) 25.2 (12.9) 25.0 (12.8) 50.3 (25.7) 53.7 (27.4) 67.0 (34.2)	

eTable 8. Distribution of Prognostic Factors Between the Study Groups Before and After IPTW Weighting Adjustment for HIPEC With Oxaliplatin Plus Fluorouracil/Leucovorin

Unweighted comparison

	CRS alo	ne	CRS/HI	IPEC	SMD
n	376		182		
Age (mean (SD))	58.95	(14.49)	56.57	(11.44)	0.183
Priorche = 1 (%)	198	(52.5)	72	(39.6)	0.262
LN = 1 (%)	14	(3.7)	14	(7.7)	0.172
PCI (mean (SD))	23.28	(12.72)	18.27	(10.27)	0.434
CC (%)					0.996
1	165	(43.8)	157	(86.3)	
2	37	(9.8)	5	(2.7)	
3	175	(46.4)	20	(11.0)	
PSS (%)					0.446
0	118	(31.3)	39	(21.4)	
1	99	(26.3)	56	(30.8)	
2	130	(34.5)	48	(26.4)	
3	30	(8.0)	39	(21.4)	
Epic = 1 (%)	53	(14.1)	1	(0.5)	0.538
Histol = 2 (%)	179	(47.5)	64	(35.2)	0.252

Weighted comparison

	CRS alone	CRS/HIPEC	SMD
n	125.02	119.14	
Age (mean (SD))	57.56 (12.65)	57.18 (12.62)	0.030
Priorche = 1 (%)	56.6 (45.2)	52.1 (43.7)	0.030
LN = 1 (%)	4.0 (3.2)	3.8 (3.2)	0.003
PCI (mean (SD))	18.54 (11.70)	18.32 (11.41)	0.019
CC (%)			0.284
1	93.5 (74.7)	94.6 (79.4)	
2	13.9 (11.1)	4.5 (3.8)	
3	17.7 (14.1)	20.0 (16.8)	
PSS (%)			0.045
0	32.9 (26.3)	33.0 (27.7)	
1	42.2 (33.8)	38.8 (32.6)	
2	37.8 (30.2)	36.8 (30.9)	
3	12.1 (9.7)	10.5 (8.8)	
Epic = 1 (%)	1.2 (0.9)	1.0 (0.8)	0.011
Histol = 2 (%)	44.4 (35.5)	42.6 (35.8)	0.005

eTable 9. Distribution of Prognostic Factors Between the Study Groups Before and After IPTW Weighting Adjustment for HIPEC With Other Oxaliplatin-Based **Combinations**

	Unweighted o	comparison			
n	CRS alo	one	CRS, 88	HIPEC	SMD
Age (mean (SD))	58.95 ((14.49)		(11.54)	0.434
Priorche = 1 (%)		(52.5)		(31.8)	0.429
LN = 1 (%) PCI (mean (SD))	14 (23.28 ((3.7)		(4.5) (9.27)	0.042
CC (%)	23.20	(12.72)	10.10	(3.27)	1.359
1		(43.8)		(95.5)	
2 3		(9.8) (46.4)		(1.1) (3.4)	
PSS (%)	175 ((40.4)	J	(3.4)	0.896
0		(31.3)		(15.9)	
1 2		(26.3)		(30.7)	
3		(34.5) (8.0)		(14.8) (38.6)	
Epic = 1 (%)		(14.1)	7	(8.0)	0.196
Histol = 2 (%)	179 ((47.5)	14	(15.9)	0.721
	Weighted co	mparison			
		-			
	CRS alo	_	CRS/HI	IPEC	SMD
n	62.38	one	58.48		-
Age (mean (SD))	62.38 53.98	one (12.05)	58.48 53.68	(12.39)	0.025
Age (mean (SD)) Priorche = 1 (%) ln = 1 (%)	62.38 53.98 21.9 2.2	(12.05) (35.0) (3.5)	58.48 53.68 20.7 2.3	(12.39) (35.5) (4.0)	-
Age (mean (SD)) Priorche = 1 (%) ln = 1 (%) PCI (mean (SD))	62.38 53.98 21.9 2.2	(12.05) (35.0)	58.48 53.68 20.7 2.3	(12.39) (35.5)	0.025 0.009 0.026 0.018
Age (mean (SD)) Priorche = 1 (%) ln = 1 (%) PCI (mean (SD)) CC (%)	62.38 53.98 21.9 2.2 18.26	(12.05) (35.0) (3.5) (11.10)	58.48 53.68 20.7 2.3 18.07	(12.39) (35.5) (4.0) (10.04)	0.025 0.009 0.026
Age (mean (SD)) Priorche = 1 (%) ln = 1 (%) PCI (mean (SD))	62.38 53.98 21.9 2.2 18.26	(12.05) (35.0) (3.5)	58.48 53.68 20.7 2.3 18.07	(12.39) (35.5) (4.0)	0.025 0.009 0.026 0.018
Age (mean (SD)) Priorche = 1 (%) ln = 1 (%) PCI (mean (SD)) CC (%) 1 2 3	62.38 53.98 21.9 2.2 18.26	(12.05) (35.0) (3.5) (11.10)	58.48 53.68 20.7 2.3 18.07 54.5	(12.39) (35.5) (4.0) (10.04)	0.025 0.009 0.026 0.018 0.324
Age (mean (SD)) Priorche = 1 (%) In = 1 (%) PCI (mean (SD)) CC (%) 1 2 3 PSS (%)	62.38 53.98 21.9 2.2 18.26 54.3 5.5 2.6	(12.05) (35.0) (3.5) (11.10) (87.0) (8.8) (4.2)	58.48 53.68 20.7 2.3 18.07 54.5 1.0 3.0	(12.39) (35.5) (4.0) (10.04) (93.2) (1.7) (5.1)	0.025 0.009 0.026 0.018
Age (mean (SD)) Priorche = 1 (%) ln = 1 (%) PCI (mean (SD)) CC (%) 1 2 3	62.38 53.98 21.9 2.2 18.26 54.3 5.5 2.6	(12.05) (35.0) (3.5) (11.10) (87.0) (88.8)	58.48 53.68 20.7 2.3 18.07 54.5 1.0 3.0	(12.39) (35.5) (4.0) (10.04) (93.2) (1.7)	0.025 0.009 0.026 0.018 0.324
Age (mean (SD)) Priorche = 1 (%) ln = 1 (%) PCI (mean (SD)) CC (%) 1 2 3 PSS (%) 0 1 2	62.38 53.98 21.9 2.2 18.26 54.3 5.5 2.6 14.3 22.3 13.0	(12.05) (35.0) (3.5) (11.10) (87.0) (8.8) (4.2) (22.9) (35.8) (20.8)	58.48 53.68 20.7 2.3 18.07 54.5 1.0 3.0 13.8 21.4 12.2	(12.39) (35.5) (4.0) (10.04) (93.2) (1.7) (5.1) 3 (23.6) 4 (36.6) 2 (20.8)	0.025 0.009 0.026 0.018 0.324
Age (mean (SD)) Priorche = 1 (%) ln = 1 (%) PCI (mean (SD)) CC (%) 1 2 3 PSS (%) 0 1 2 3	62.38 53.98 21.9 2.2 18.26 54.3 5.5 2.6 14.3 22.3 13.0 12.8	(12.05) (35.0) (3.5) (11.10) (87.0) (8.8) (4.2) (22.9) (35.8) (20.8) (20.5)	58.48 53.68 20.7 2.3 18.07 54.5 1.0 3.0 13.8 21.4 12.2 11.5	(12.39) (35.5) (4.0) (10.04) (93.2) (1.7) (5.1) 3 (23.6) 4 (36.6) 2 (20.8) L (19.0)	0.025 0.009 0.026 0.018 0.324
Age (mean (SD)) Priorche = 1 (%) ln = 1 (%) PCI (mean (SD)) CC (%) 1 2 3 PSS (%) 0 1 2	62.38 53.98 21.9 2.2 18.26 54.3 5.5 2.6 14.3 22.3 13.0 12.8 7.8	(12.05) (35.0) (3.5) (11.10) (87.0) (8.8) (4.2) (22.9) (35.8) (20.8)	58.48 53.68 20.7 2.3 18.07 54.5 1.0 3.0 13.8 21.4 12.2 11.2 6.2	(12.39) (35.5) (4.0) (10.04) (93.2) (1.7) (5.1) 3 (23.6) 4 (36.6) 2 (20.8)	0.025 0.009 0.026 0.018 0.324

SMD: standard mean difference. We set SMD < 0.3 as perfect balance for the IPTW propensity score matching; Priorche: prior systemic chemotherapy; LN: lymph node; PCI: peritoneal cancer index; PSS: prior surgical score; Epic: early postoperative peritoneal chemotherapy; Histology: 1: low grade; 2: high grade; CC: completeness of cytoreduction score

eTable 10. Surgical Outcomes of Patients With PMP Undergoing CRS-HIPEC (n = 1548) and CRS Alone (n = 376) (unweighted comparison)

	CRS HIPEC	CRS
	n (%)	n (%)
90-day mortality	48 (3.1%)	33 (8.8%)
30-day mortality	24 (1.6%)	16 (4.3%)
Return to operating toom	143 (9.2%)	35 (9.3%)
Grade 3-5 morbidity	506 (32.7%)	109 (29.0%)
Surgical complications		
Septic collection	125 (8.1%)	17 (4.5%)
Gastric/bowel fistula	121 (7.8%)	37 (9.8%)
Pancreatic fistula	32 (2.1%)	1 (0.3%)
Bleeding	91 (5.9%)	14 (3.7%)
Genitourinary	10 (0.6%)	3 (0.8%)
Thromboembolic event	6 (0.4%)	1 (0.3%)
Isolated cardiac failure	58 (3.8%)	5 (1.3%)
Pneumonia	65 (4.2%)	12 (3.2%)
Pleural	146 (9.4%)	12 (3.2%)
Pneumothorax	38 (3.0%)	0 (0%)
Systemic toxicities		
Bone marrow toxicity	16 (1.0%)	0 (0%)
Renal Failure	35 (2.3%)	2 (0.5%)
Disseminated intravascular coagulation	12 (0.8%)	2 (0.5%)

eTable 11. Unweighted Comparison of the Distribution of the Prognostic Factors and Outcomes Between Included and Excluded Cases

Age (median, IQR) 56.0 [45.0, 65.0] 54.5 [45.0, 62.9] 0.089 Missing (%) 0 (0.0) 414 (26.3) 0 Priorchemo N (%) 727 (37.8) 197 (32.1) 0.119 Missing 0 958 0.148 LN positive 133 (6.9) 55 (3.6) 0.148 negative 1791 (93.1) 1469 (96.4) 0.148 Missing 0 47 0.083 PCI (mean, IQR) 20.0 [10.0, 29.0] 19.0 [9.0, 29.0] 0.083 missing 0 987 0.083 0.083 CC 0/1 1516 (78.8) 1259 (80.3) 0.083 0.083 PSS 0 473 (24.6) 201 (21.0) 0.235 0.038 0.038 0.031 0.038 0.031 0.038 0.031 0.038 0.031 0.038 0.038 0.031 0.038 0.031 0.038 0.038 0.038 0.031 0.038 0.038 0.038 0.031 0.038 0.031 </th <th>Parameters</th> <th>Categories</th> <th>Included (n=1924)</th> <th>Excluded (n=1571)</th> <th>SMD</th>	Parameters	Categories	Included (n=1924)	Excluded (n=1571)	SMD
Priorchemo N (%) 727 (37.8) 197 (32.1) 0.119 Missing 0 958 1.48 LN positive 133 (6.9) 55 (3.6) 0.148 Negative 1791 (93.1) 1469 (96.4) 1469 (96.4) Missing 0 47 47 PCI (mean, IQR) 20.0 [10.0, 29.0] 19.0 [9.0, 29.0] 0.083 missing 0 987 0.038	Age	(median, IQR)	56.0 [45.0, 65.0]	54.5 [45.0, 62.9]	0.089
Missing		Missing (%)	0 (0.0)	414 (26.3)	
LN positive negative 133 (6.9) 55 (3.6) 0.148 negative 1791 (93.1) 1469 (96.4) 47 PCI (mean, IQR) 20.0 [10.0, 29.0] 19.0 [9.0, 29.0] 0.083 missing 0 987 0.038 CC 0/1 1516 (78.8) 1259 (80.3) 0.038 2/3 408 (21.2) 308 (19.7) 0.038 PSS 0 473 (24.6) 201 (21.0) 0.235 1 566 (29.4) 211 (22.0) 0.235 2 585 (30.4) 336 (35.1) 33 300 (15.6) 209 (21.8) Missing 0 614 0.000 0.000 0.459 0.0459 EPIC yes 303 (15.7) 525 (35.2) 0.459 0.0459 Missing 0 81 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000	Priorchemo	N (%)	727 (37.8)	197 (32.1)	0.119
Regative 1791 (93.1)		Missing	0	958	
Missing	LN	positive	133 (6.9)	55 (3.6)	0.148
PCI (mean, IQR) 20.0 [10.0, 29.0] 19.0 [9.0, 29.0] 0.083 missing 0 987 CC 0/1 1516 (78.8) 1259 (80.3) 0.038 2/3 408 (21.2) 308 (19.7) 0.038 Missing 0 4 4 PSS 0 473 (24.6) 201 (21.0) 0.235 1 566 (29.4) 211 (22.0) 2.2 585 (30.4) 336 (35.1) 3.3 300 (15.6) 209 (21.8) 0.0 44 0.0 0		negative	1791 (93.1)	1469 (96.4)	
Missing		Missing	_	47	
CC 0/1 1516 (78.8) 1259 (80.3) 0.038 2/3 408 (21.2) 308 (19.7) 308 (19.7) Missing 0 4 4 PSS 0 473 (24.6) 201 (21.0) 0.235 1 566 (29.4) 211 (22.0) 2 2 585 (30.4) 336 (35.1) 3 3 300 (15.6) 209 (21.8) 0 Missing 0 614 0 EPIC yes 303 (15.7) 525 (35.2) 0.459 no 1621 (84.3) 965 (64.8) 0 4 Missing 0 81 0 112 0 186 0 186 0 186 0 186 0 0 186 0 0 186 0 0 186 0 0 186 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 <t< td=""><td>PCI</td><td>(mean, IQR)</td><td>20.0 [10.0, 29.0]</td><td>-</td><td>0.083</td></t<>	PCI	(mean, IQR)	20.0 [10.0, 29.0]	-	0.083
2/3			0	987	
Missing	CC				0.038
PSS 0 473 (24.6) 201 (21.0) 0.235 1 566 (29.4) 211 (22.0) 2 585 (30.4) 336 (35.1) 3 300 (15.6) 209 (21.8) Missing 0 614 EPIC yes 303 (15.7) 525 (35.2) 0.459 no 1621 (84.3) 965 (64.8) Missing 0 81 Histology Low grade 1253 (65.1) 1075 (73.7) 0.186 High grade 671 (34.9) 384 (26.3) Missing 0 112 Outcome Survival -5 year OS (%, Cl95%) 0.649 (0.621-0.677) 0.767 (0.741-0.792) <0.001 (p-10 year OS (%, Cl95%) 0.513 (0.465-0.567) 0.669 (0.629-0.710) value) missing 0 19 90-day mortality (%) 81 (4.2) 48 (3.1) 0.062 missing 0 0 0 30-day mortality (%) 40 (2.1) 29 (1.8) 0.017 missing 0 0 0 Return to OR (%) 82 (9.3) 82 (5.5) 0.145 missing 0 0 74 Severe morbidity (%) 615 (32.0) 283 (18.6) 0.311		2/3	408 (21.2)	308 (19.7)	
1		Missing	_	<u>-</u>	
2 585 (30.4) 336 (35.1) 3 300 (15.6) 209 (21.8) Missing 0 614 EPIC yes 303 (15.7) 525 (35.2) 0.459 no 1621 (84.3) 965 (64.8) Missing 0 81 Histology Low grade 1253 (65.1) 1075 (73.7) 0.186 High grade 671 (34.9) 384 (26.3) Missing 0 112 Outcome Survival - 5 year OS (%, Cl95%) 0.649 (0.621-0.677) 0.767 (0.741-0.792) <0.001 (p-10 year OS (%, Cl95%) 0.513 (0.465-0.567) 0.669 (0.629-0.710) value) missing 0 19 90-day mortality (%) 81 (4.2) 48 (3.1) 0.062 missing 0 0 0 Return to OR (%) 82 (9.3) 82 (5.5) 0.145 missing 0 74 Severe morbidity (%) 615 (32.0) 283 (18.6) 0.311	PSS	0	473 (24.6)	201 (21.0)	0.235
3 300 (15.6) 209 (21.8) Missing		1	566 (29.4)	211 (22.0)	
Missing		2	585 (30.4)	336 (35.1)	
EPIC yes 303 (15.7) 525 (35.2) 0.459 no 1621 (84.3) 965 (64.8) Missing 0 81 Histology Low grade 1253 (65.1) 1075 (73.7) 0.186 High grade 671 (34.9) 384 (26.3		3	300 (15.6)	209 (21.8)	
no 1621 (84.3) 965 (64.8) Missing 0 81 Histology Low grade 1253 (65.1) 1075 (73.7) 0.186 High grade 671 (34.9) 384 (26.3) 384 (26.3) Missing 0 112 Outcome Survival 5 year OS (%, Cl95%) 0.649 (0.621-0.677) 0.767 (0.741-0.792) <0.001 (p-value)		Missing	0	614	
Missing 0 81 Histology Low grade 1253 (65.1) 1075 (73.7) 0.186 High grade 671 (34.9) 384 (26.3)	EPIC	yes	303 (15.7)	525 (35.2)	0.459
Histology Low grade 1253 (65.1) 1075 (73.7) 0.186 High grade 671 (34.9) 384 (26.3) Missing 0 112 Outcome Survival -5 year OS (%, Cl95%) 0.649 (0.621-0.677) 0.767 (0.741-0.792) <0.001 (p-0.001		no	1621 (84.3)	965 (64.8)	
High grade 671 (34.9) 384 (26.3) Missing 0 112 Outcome 5 year OS (%, Cl95%) 0.649 (0.621-0.677) 0.767 (0.741-0.792) <0.001 (p-10 year OS (%, Cl95%)		Missing	0	81	
Missing 0 112 Outcome Survival -5 year OS (%, Cl95%) 0.649 (0.621-0.677) 0.767 (0.741-0.792) <0.001 (p-	Histology	Low grade	1253 (65.1)	1075 (73.7)	0.186
Outcome Survival - 5 year OS (%, Cl95%) 0.649 (0.621-0.677) 0.767 (0.741-0.792) <0.001 (p-		High grade	671 (34.9)	384 (26.3)	
Survival 0.649 (0.621-0.677) 0.767 (0.741-0.792) <0.001 (p-0.001) - 10 year OS (%, Cl95%) 0.513 (0.465-0.567) 0.669 (0.629-0.710) value) missing 0 19 90-day mortality (%) 81 (4.2) 48 (3.1) 0.062 missing 0 0 0 30-day mortality (%) 40 (2.1) 29 (1.8) 0.017 missing 0 0 0 Return to OR (%) 82 (9.3) 82 (5.5) 0.145 missing 0 74 0 Severe morbidity (%) 615 (32.0) 283 (18.6) 0.311		Missing	0	112	
- 5 year OS (%, Cl95%) 0.649 (0.621-0.677) 0.767 (0.741-0.792) <0.001 (p-					
- 10 year OS (%,Cl95%) 0.513 (0.465-0.567) 0.669 (0.629-0.710) value) missing 0 19 90-day mortality (%) 81 (4.2) 48 (3.1) 0.062 missing 0 0 0 30-day mortality (%) 40 (2.1) 29 (1.8) 0.017 missing 0 0 0 Return to OR (%) 82 (9.3) 82 (5.5) 0.145 missing 0 74 0 Severe morbidity (%) 615 (32.0) 283 (18.6) 0.311					
missing 0 19 90-day mortality (%) 81 (4.2) 48 (3.1) 0.062 missing 0 0 30-day mortality (%) 40 (2.1) 29 (1.8) 0.017 missing 0 0 Return to OR (%) 82 (9.3) 82 (5.5) 0.145 missing 0 74 Severe morbidity (%) 615 (32.0) 283 (18.6) 0.311					•
90-day mortality (%) 81 (4.2) 48 (3.1) 0.062 missing 0 0 30-day mortality (%) 40 (2.1) 29 (1.8) 0.017 missing 0 0 Return to OR (%) 82 (9.3) 82 (5.5) 0.145 missing 0 74 Severe morbidity (%) 615 (32.0) 283 (18.6) 0.311	- 10 year OS (%,CI95%)		0.513 (0.465-0.567)	0.669 (0.629-0.710)	value)
missing 0 0 30-day mortality (%) 40 (2.1) 29 (1.8) 0.017 missing 0 0 Return to OR (%) 82 (9.3) 82 (5.5) 0.145 missing 0 74 Severe morbidity (%) 615 (32.0) 283 (18.6) 0.311	missing		0	19	
30-day mortality (%) 40 (2.1) 29 (1.8) 0.017 missing 0 0 Return to OR (%) 82 (9.3) 82 (5.5) 0.145 missing 0 74 Severe morbidity (%) 615 (32.0) 283 (18.6) 0.311			81 (4.2)	48 (3.1)	0.062
missing 0 0 Return to OR (%) 82 (9.3) 82 (5.5) 0.145 missing 0 74 Severe morbidity (%) 615 (32.0) 283 (18.6) 0.311			0	Ů Ú	
missing 0 0 Return to OR (%) 82 (9.3) 82 (5.5) 0.145 missing 0 74 Severe morbidity (%) 615 (32.0) 283 (18.6) 0.311	30-day mortality	(%)	40 (2.1)	29 (1.8)	0.017
Return to OR (%) 82 (9.3) 82 (5.5) 0.145 missing 0 74 Severe morbidity (%) 615 (32.0) 283 (18.6) 0.311					
missing 0 74 Severe morbidity (%) 615 (32.0) 283 (18.6) 0.311			82 (9.3)	82 (5.5)	0.145
Severe morbidity (%) 615 (32.0) 283 (18.6) 0.311		•	· · · · · · · · · · · · · · · · · · ·		
			615 (32.0)	283 (18.6)	0.311
THOUSING U	missing	. ,	0	50	

SMD: standardized mean difference

eTable 12. Unweighted Distribution of Prognostic Factors Between the Study Group s in the Cases That Were Excluded Due to Incomplete Data

St	ratifi	ed by hipec		
		CRS alone	CRS/HIPEC	SMD
n		223	1342	
Age (median [IQR])		58.40 [48.50, 67.00]	54.00 [44.10, 61.70]	0.322
Priorche (%)	0	53 (68.8)	362 (68.3)	0.011
	1	24 (31.2)	168 (31.7)	
LN (%)	0	215 (98.2)	1248 (96.1)	0.126
	1	4 (1.8)	51 (3.9)	
PCI (median [IQR])		15.00 [7.75, 26.50]	19.00 [10.00, 29.00]	0.146
CC (%)	1	223 (100.0)	1338 (100.0)	<0.001
pss (%)	0	11 (23.9)	188 (20.8)	0.311
	1	7 (15.2)	203 (22.4)	
	2	13 (28.3)	321 (35.4)	
	3	15 (32.6)	194 (21.4)	
Epic (%)	0	161 (88.0)	801 (61.4)	0.641
	1	22 (12.0)	503 (38.6)	
Histol (%)	1	165 (77.5)	908 (73.0)	0.102
	2	48 (22.5)	335 (27.0)	
Severe morbidity_(%) 0	160 (83.8)	1073 (81.0)	0.072
_	1	31 (16.2)	251 (19.0)	
10-year OS (%, 95%C	I)	30.7% [20.1-46.7%]	71.7% [67.5-76.0%]	0<0.001